



1/83




FIG. 1

2/83




FIG.2

3/83




FIG. 3A



FIG. 3B



FIG. 3C




FIG. 3D

4/83




FIG.4

5/83




FIG. 5A




FIG. 5B




FIG. 5C

FIG. 5D




FIG. 5E




FIG. 5F

6/83




FIG.6

7/83




FIG.7

8/83




FIG.8

9/83




FIG.9

10/83




FIG.10

11/83




FIG.11

12/83




FIG.12

13/83




FIG.13

14/83




FIG.14A




FIG.14B




FIG.14C

15/83




FIG. 15

16/83

1 GGATCATGAT GATAACAAT GTATGGTGCT AATGTTGCTT CAACAACAAT TCTGTTGAAC
61 TGTGTTTTCA TGTTCGCCAA CAAGCACCTT TATACTCGGT GGCCTCCCCA CCACCAACTT
121 TTTTGCACTG CAAAAAACA CGCTTTTGCA CGGGGGCCCA TACATAGTAC AAACCTCTACG
181 TTTCTAGAC TATTTTACAT AAATAGTCTA CACGTTGTGA TAGCTCCAA ATACACTACC
241 ACACATTGAA CCTTTTGGCA GTGCAAAAAA GTACGTGTGCG GCAGTCACGT AGGCCGGCCT
301 TATCGGGTGG CGTCCTGTCA CGTACGAATC ACATTATCGG ACCGGACGAG TGTGTCTTA
361 TCGTGACAGG ACGCCAGCTT CCTGTGTTGC TAACCGCAGC CGGACGCAAC TCCTTATCGG
421 AACAGGACGC GCCTCCATAT CAGCCGCGCG TTAATCTCATG CGCGTGACCG GACACGAGGC
481 GCGCGTCCCG CTTATCGGC CTATAAATAC AGCCCGCAAC GATCTGGTAA ACACAGTTGA
541 ACAGCATCTG TTCGAATTTA

TATA
Start of Transcription

FIG.16

17/83




FIG.17

18/83




FIG.18

19/83




FIG. 19A




FIG. 19B

21/83




FIG.20

22/83




FIG. 21

23/83





FIG.22

24/83

TROPIX ASSAY OF Sf21 CELLS TRANSFECTED WITH ALTERNATE
 SELECTION PROMOTERS AFTER 1 WEEK OF SELECTION



- GP64-SHORT#1, 20µg/mL BLAST
- GP64-SHORT#1, 100µg/mL BLAST
- GP64-SHORT#2, 20µg/mL BLAST
- GP64-SHORT#2, 100µg/mL BLAST
- PE38-LONG#1, 20µg/mL BLAST
- PE38-LONG#1, 100µg/mL BLAST
- PE38-LONG#2, 20µg/mL BLAST
- PE38-LONG#2, 100µg/mL BLAST
- PE38-SHORT#1, 20µg/mL BLAST
- PE38-SHORT#1, 100µg/mL BLAST
- PE38-SHORT#2, 20µg/mL BLAST
- PE38-SHORT#2, 100µg/mL BLAST
- pIB-LacZ CONTROL, 20µg/mL BLAST
- pIB-LacZ CONTROL, 100µg/mL BLAST

FIG.23

25/83




FIG.24

26/83

Calmodulin TFIIs




FIG.25A




FIG.25B

27/83






FIG.26

28/83



29/83

HTP PROTOCOL FOR USE WITH BACULODIRECT (TM)




FIG.28

30/83




FIG.29

31/83




FIG.30

32/83




FIG.31

33/83

VIRUS \ TITER pfu/ml	TRANSFECT	INFECT
BACULODIRECT™	9.8×10^6	6.9×10^8
BAC TO BAC	6.9×10^6	7.2×10^8
MAXBAC	N/A	3.6×10^8

TITER COMPARISON OF THE THREE VIRUSES BY USING TCID₅₀

VIRUS \ TITER pfu/ml	TRANSFECT	INFECT.
BACULODIRECT™	6×10^6	3×10^8
BAC TO BAC	8×10^6	5×10^8
MAXBAC	N/A	3×10^8

TITER COMPARISON OF THE THREE VIRUSES BY USING PLAQUE ASSAY

FIG.32

34/83




FIG.33

35/83




FIG.34

36/83




FIG.35

37/83




FIG.36A




FIG.36B

38/83




FIG.36C

39/83




FIG.36D

40/83




FIG.37A




FIG.37B




FIG.37C

41/83




FIG.38A

[Bsd] IN PLATE \ LR REACTION	DEST ALONE	DEST + CAT
NO Bsd	24	320^1 $(12/24 = 50\%)^2$
50 μ g/ml Bsd	0	162 $(24/24 = 100\%)^2$

¹SEE PHOTO ABOVE

²PERCENTAGE OF CORRECT COLONIES

FIG.38B

42/83




FIG.39A




FIG.39B

43/83

EXAMPLES OF PRODUCTION TITERS (Bsd^R cfu/ml)

	EMPTY	LacZ	GFP	CAT	PKC
EXP 1	6 x 10 ⁶	5 x 10 ⁵	4 x 10 ⁶	N.D.	N.D.
EXP 2	3 x 10 ⁷	3 x 10 ⁵	6 x 10 ⁶	8 x 10 ⁶	N.D.
EXP 3	7 x 10 ⁶	6 x 10 ⁵	2 x 10 ⁶	1 x 10 ⁷	3 x 10 ⁶
AVG	1.4 x 10 ⁷	4.7 x 10 ⁵	4 x 10 ⁶	9 x 10 ⁶	3 x 10 ⁶

N.D. = NOT DETERMINED


FIG.40

pLenti6/V5-GW/lacZ



FIG. 41A


pLenti6/V5-dT/GFP



Brightfield

FIG. 41B


pLenti6/V5-dT/GFP



Fluorescent


FIG. 41C

45/83



lacZ lacZ CAT CAT GFP

FIG.42A



PKC GFP

FIG.42B

46/83




FIG.43A

47/83




FIG. 43B

48/83






FIG. 44A

49/83



rKAT6-lacZ retrovirus



pLenti6/V5-GW/lacZ


FIG.44B

50/83

10 days



rKAT6-lacZ retrovirus




pLenti6/V5-GW/lacZ lentivirus

FIG.45A

6 weeks



rKAT6-lacZ retrovirus



pLenti6/V5-GW/lacZ lentivirus

FIG.45B

51/83




FIG. 46A

52/83

UB forward priming site

2881 TTGGCGAGTG TGTTTTGTGA AGTTTTTTAG GCACCTTTTG AATGTAATC ATTTGGGICA ATATGTAATT TTCAGTGTTA

2961 GACTAGTAAA TTGTCGCTA AATTCGCGC GTTTTTGGCT TTTTGTAG ACGAAGCTTG GTACCGAGCT CGGATCCACT

4762

3079

3041 AGTCCAGTGT GGTGGAATTC TGCAGATATC AACAAAGTTTG TACAAAAAG CAGGCTN ... NAC CCA GCT TTC
 ACGTCTATAG TTGTTCAAC ATGTTTTTC GTCCGAN ... NTG GGT CGA AAG

aatB1

atB2

... Pro Ala Phe

Leu Tyr Lys Val Val Asp Ile Gln His Ser Gly Gly Arg Ser Ser Leu Gly Pro Arg Phe Glu
 4763 TTG TAC AAA GTG GTT GAT ATC CAG CAC AGT GGC GGC CGC TCG AGT CTA GAG GGC CCG CGG TTC GAA
 AAC ATG TTT CAC CAA CTA TAG GTC GTG TCA CCG CCG GCG AGC TCA GAT CTC CCG GGC GCC AAG CTT

*** *** ***

Gly Lys Pro Ile Pro Asn Pro Leu Leu Gly Leu Asp Ser Thr Arg Thr Gly
 4829 GGT AAG CCT ATC CCT AAC CCT CTC CTC GGT CTC GAT TCT ACG CGT ACC GGT TAG TAA TGA GTTT
 CCA TTC GGA TAG GGA TTC GGA GAG CCA CCA GAG CTA AGA TGC GCA TGG CCA

v5 epitope

v5 (C-term) reverse priming site

FIG.46B

53/83

5' end of *U₆* promoter

1796 CCGATCTGGC CTCGCGCGCG GGTTTGGCG CTCCCGCGG GCGCCCCCT CTCACGGCG AGCGTGCCA CGTCAGACGA

1876 AGGGCGCAGG AGCGTCCIGA TCCTTCGCGC Sp 1 GGGACGCTCA GGACAGGGC CCGTGCTCA TAAGACTCG CCTTAGAAC

1956 CCAGTATCAG CAGAAGGACA TTTTAGGACG GGAATTGGT GACTCTAGG CACTGGTTT CTTCCAGAG AGCGGAACAG

2036 GCGAGGAAA GTAGTCCCTT CTCGGCGATT CTGCGGAGG ATCTCCGTG Sp 1 GCGGTGAAC GCCGATGATT ATATAAGGAC

2116 GCGCCGGGTG TGGCACAGCT AGTTCCGTG CAGCCGGGAT TTGGTCGG GTTCTTGTT GTGGATCGCT GTGATCGTCA

Start of Transcription

Exon 1

5' end of Intron 1

2196 CTGGTGAGT AGCGGGCTG TGGCTGGCC GGGGCTTTG TGGCCGCCG GCCGCTCGT GGGACGGAAG CGTGTGGAGA

2276 GACCGCCAAG GGCTGTAGTC TGGTCCGG AGCAAGGTTG CCCTGAACTG GGGGTTGGG GGAGCGCAGC AAAATGGCGG

2356 CTGTTCCCGA GTCTTGAATG GAAGACGCTT GTGAGGCGG CTGTGAGTC GTTGAAACAA GGTGGGGGC ATGGTGGCG

FIG. 46C

54/83

2436 GCAAGAACCC AAGGTCTTGA GGCCTTCGCT AATGCGGGAA AGCTCTTATT CGGGTGAGAT GGGCTGGGC ACCATCTGGG

2516 GACCCTGACG TGAAGTTTGT CACTGACTGG AGAACTCGGT TTGTCGTCTG TTGCGGGGC GGCAGTTATG CCGTGCCGTT

2596 GGGCAGTGCA CCCGTACCTT TGGGAGCGG CGCCCTCGTC GTGTCGTGAC GTCACCCGTT CTGTTGGCTT ATAATGCAGG

2676 GTGGGGCCAC CTGCCGGTAG GTGTGCGGTA GGCTTTTCTC CGTCGCAGGA CGCAGGGTTC GGGCCTAGGG TAGGCTCTCC

2756 TGAATCGACA GGCGCCGGAC CTCTGGTGAG GGGAGGGATA AGTGAGGCGT CAGTTTCTTT GGTCGGTTTT ATGTACCTAT

2836 CTTCCTAAGT AGCTGAAGCT CCGGTTTTGA ACTATGCGCT CGGGTTGGC GAGTGTGTTT TGTGAAGTTT TTTAGGCACC

2916 TTTIGAAATG TAATCATTTG GGTCATATG TAATTTTCAG TGTTAGACTA GTAAATTGTC CGCTAAATTC TGGCCGTTTT

UB Forward priming site

3' end of Intron 1
2996 TGGCTTTTTT GTTAGACGAA GCTTGG....
5' end of Exon 2

FIG.46D

55/83




FIG.47

56/83




FIG.48

57/83




FIG.49

58/83




FIG.50

59/83




FIG. 51A





FIG. 51B

60/83



$pcDNA3.1 lacZ-stop^{TAG}-GFP$

FIG. 52

61/83





FIG.53

62/83



ORF12 (BC000141)


ORF7 (BC000997)

ORF6 (BC003357)

GFP-V5

12	6	7	lacZ
-	+	-	+
-	-	+	-
-	+	-	+

tRNA:



Anti-V5 blot

FIG. 54

63/83




FIG. 55B




FIG. 55A




FIG. 56

65/83




FIG.57

66/83




FIG.58

67/83




FIG.59

68/83




FIG.60

69/83




FIG. 61A

70/83




FIG. 61B

71/83





FIG.62



72/83

YOUR STABLE MAMMALIAN CELL
 LINE OF INTEREST


1. EXPRESS NATIVE RECOMBINANT PROTEIN OR ADD THE
 TAG-ON-DEMAND™ SUPPRESSOR SUPERNATANT TO CELLS,
 AND HARVEST CELLS AFTER 24-28 HOURS TO ASSAY
 FOR C-TERMINALLY-TAGGED RECOMBINANT PROTEIN.



+ TAG-ON-DEMAND™
 SUPPRESSOR SUPERNATANT



NATIVE RECOMBINANT PROTEIN



C-TERMINALLY-TAGGED
 RECOMBINANT PROTEIN

FIG. 63

73/83




FIG.64

74/83






FIG.65

75/83





76/83

FIG.67

77/83




FIG.68

78/83




FIG.69

79/83




FIG.70A

80/83




FIG. 70B

81/83




FIG.71

82/83




FIG.72

83/83




FIG.73